Aspirin use and the prevention of acute ischemic cranial nerve palsy.
OBJECTIVE
To assess the relationship of aspirin use and ischemic cranial nerve palsies among patients with diabetes mellitus and hypertension.


METHODS
This retrospective case-control study involved 100 patients with ischemic cranial nerve palsies in association with diabetes, hypertension, or both (palsy cases) and 163 age-matched and sex-matched patients with diabetes, hypertension, or both but without ischemic cranial nerve palsies (nonpalsy control subjects). Comparisons were made with respect to duration of diabetes, dose and duration of aspirin use, dose and duration of tobacco use, and presence of cardiac or cerebrovascular disease.


RESULTS
There were 20 oculomotor, 33 trochlear, 37 abducens, and 10 facial nerve palsy cases. The median duration of diabetes was 6 years for cases and 7 years for control subjects. There were 34 cases (34%) who had used aspirin for a mean duration of 5.5 years before the onset of the cranial nerve palsy and 49 control subjects (30.1%) who had used aspirin for a mean duration of 4.3 years. There were no significant differences between cases and control subjects for duration of diabetes (P =.94); aspirin use (P =.51), duration (P =.50), and dosage (P =.89); tobacco use (P =.73) and consumption (P =.45); and proportion of cardiac disease (P =.17). Cerebrovascular disease was significantly less common among palsy cases than nonpalsy control subjects (P<.001). There was no significant difference in the odds of a patient having cranial nerve palsy in the aspirin group compared with the nonaspirin group (odds ratio, 1.12; 95% confidence interval, 0.70-2.04).


CONCLUSIONS
Aspirin use was not associated with a reduced rate of ischemic third, fourth, sixth, and seventh nerve palsies among patients with diabetes mellitus and hypertension. Aspirin appears to be ineffective in preventing ischemic third, fourth, sixth, and seventh cranial nerve palsies. Patients with ischemic cranial nerve palsy have a significantly lower rate of strokes and transient ischemic attacks than patients who have diabetes or hypertension but who do not have a history of cranial nerve palsy.
Johnson
L N
LN
Neuro-ophthalmology Unit, Mason Eye Institute, University of Missouri, Columbia, MO 65212, USA. JohnsonLN@health.missouri.edu
Stetson
S W
SW
Krohel
G B
GB
Cipollo
C L
CL
Madsen
R W
RW
D000208:Acute Disease; D000368:Aged; D000369:Aged, 80 and over; D001241:Aspirin / Q000627:therapeutic use*; D016022:Case-Control Studies; D003389:Cranial Nerve Diseases / Q000209:etiology / Q000517:prevention & control*; D003391:Cranial Nerves / Q000098:blood supply* / Q000473:pathology; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use*; D048909:Diabetes Complications; D004172:Diplopia / Q000209:etiology / Q000503:physiopathology; D005158:Facial Paralysis / Q000209:etiology / Q000503:physiopathology; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications; D007511:Ischemia / Q000209:etiology / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D012189:Retrospective Studies
D016861:Cyclooxygenase Inhibitors; D010975:Platelet Aggregation Inhibitors; D001241:Aspirin